Yuyu Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Yuyu Pharma has a total shareholder equity of ₩120.4B and total debt of ₩38.6B, which brings its debt-to-equity ratio to 32%. Its total assets and total liabilities are ₩198.2B and ₩77.9B respectively.
Key information
32.0%
Debt to equity ratio
₩38.57b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩32.35b |
| Equity | ₩120.36b |
| Total liabilities | ₩77.86b |
| Total assets | ₩198.21b |
Recent financial health updates
Here's Why Yuyu Pharma (KRX:000220) Has A Meaningful Debt Burden
Apr 02
Yuyu Pharma (KRX:000220) Seems To Use Debt Quite Sensibly
Dec 20Recent updates
Here's Why Yuyu Pharma (KRX:000220) Has A Meaningful Debt Burden
Apr 02Should Yuyu Pharma, Inc. (KRX:000220) Be Part Of Your Dividend Portfolio?
Mar 08The Yuyu Pharma (KRX:000220) Share Price Has Gained 12% And Shareholders Are Hoping For More
Feb 10
We Wouldn't Rely On Yuyu Pharma's (KRX:000220) Statutory Earnings As A Guide
Jan 07Yuyu Pharma (KRX:000220) Seems To Use Debt Quite Sensibly
Dec 20Would Yuyu Pharma, Inc. (KRX:000220) Be Valuable To Income Investors?
Dec 03Financial Position Analysis
Short Term Liabilities: A000220's short term assets (₩101.6B) exceed its short term liabilities (₩50.0B).
Long Term Liabilities: A000220's short term assets (₩101.6B) exceed its long term liabilities (₩27.9B).
Debt to Equity History and Analysis
Debt Level: A000220's net debt to equity ratio (5.2%) is considered satisfactory.
Reducing Debt: A000220's debt to equity ratio has reduced from 35.2% to 32% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A000220 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A000220 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 28.3% each year